πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 416 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11608381

Methods of treatment using a leptin receptor agonist antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603407

Stable antibody formulation

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596688

Predicting outcome of treatment with an anti-Ξ±4Ξ²7 integrin antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11596696

Combination therapy with an anti-CD25 antibody-drug conjugate

ADC THERAPEUTICS SA Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597774

Antibody variable domains and antibody constructs

The Board of Regents of the University of Texas System Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597773

CD6 antibody for treatment of T-cell mediated diseases or disorders

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11576863

Formulation of an antibody and use thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11572408

Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modula

VACCINEX, INC. Β· Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11566076

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Five Prime Therapeutics, Inc. Β· Granted Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559583

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. Β· Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11555064

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548940

Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract u

Rani Therapeutics, LLC Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548953

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment c

The Regents of the University of California Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11547761

Antibody adjuvant conjugates

Bolt Biotherapeutics, Inc. Β· Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542338

CD38 modulating antibody

BLACK BELT THERAPEUTICS LIMITED Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11535869

CD8-specific antibody constructs and compositions thereof

Sana Biotechnology, Inc. Β· Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11534495

Tissue factor-targeted antibody-drug conjugate

SHANGHAI MIRACOGEN INC. Β· Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518804

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518800

Mutations that drive VH4 antibody autoreactivity

The Board of Regents of the University of Texas System Β· Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505601

Compositions and methods using a single-domain antibody binding transferrin and protein A

Nanjing Legend Biotech Co., Ltd Β· Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11485793

Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11472884

Humanized BCMA antibody and BCMA-CAR-T cells

Caribou Biosciences, Inc. Β· Granted Tue Oct 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11459381

Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumo

UNIVERSITY OF CONNECTICUT Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11453725

Methods for DNA-dependent targeting of a cell permeant antibody

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted